State-of-the-Art Technology Platforms for Antibody Discovery

3 technology platforms established, with 30 patents granted and another 45 applications in progress.

Human Antibody Transgenic Mice (BA-huMab)® + Phage Display Tech Platform

Our BA-huMab® platform features the following advantages: no humanization work is needed for antibodies, which lowers the risks in drug development and greatly improves our R&D efficiency; elicit an immune response quickly and produce a high antibody titer after immunization, antibodies identified with high affinity and high specificity
Our Phage display technology platform features the following advantages: efficient animal immunity technology, mature phage library construction technology, high-throughput and diverse phage based panning strategies, diverse evaluation capabilities for antibodies or antibody fragments

Bispecific T-cell Engager Technology Platform

Our bispecific T-cell engager format exhibits high avidity with tumor target antigen by bivalent binding to achieve better drug efficacy, and low affinity with T cells by monovalent binding to lower toxicity.
Our bispecific T-cell engager technology platform further reduces CD3 antibody binding affinity, therefore significantly reduces the risk of CRS.

ADC Technology Platform

Design, synthesis and screening potential ADC linker-payload
Identification of potential internalized antibodies
Diverse antibody conjugation technologies
Evaluation of ADC in vitro and in vivo
Process development and quality analysis for ADC products

Human Antibody Transgenic Mice (BA-huMab)® + Phage Display Tech Platform

Bispecific T-cell Engager Technology Platform

ADC Technology Platform

Production capacity

Supporting Drug Development and Enabling Enhanced Cost Efficiencies in Commercial-scale Production.

Yantai Manufacturing Site

● Over 300 employees in our manufacturing team
● GFA: 33,504.1 sq.m.
● Pilot production capacity: 1,700L
● Commercial production capacity: 8,000L
● Two production lines with 2*500L capacity for pilot production and two production lines with 3*2,000L capacity for commercial production under construction
● Meet quality standards such as GMP set by the relevant regulatory authorities of China and the EU

R&D

Technology platform

State-of-the-Art Technology Platforms for Antibody Discovery

Human Antibody Transgenic Mice (BA-huMab)® + Phage Display Tech Platform

Bispecific T-cell Engager Technology Platform

ADC Technology Platform

Differentiated Innovations and Technology Platforms

Non-Lenti Gene Delivery System

the 4th Generation CAR-T technology

Non-Gene Editing Off-the-shelf CAR-T

Boan Product Pipeline

Intellectual Property

Boan Biotech has 30 granted patents and

45 pending patent applications worldwide.

Production capacity

Yantai Manufacturing Site

Contact us

About Us

R&D

Products

News

Careers

Investors